Mesenchymal Stem Cell Therapy for Osteogenesis Imperfecta
Authors:
- 13 September 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 64 (4) , 898-903
Abstract
The aim of this study was to provide a brief overview on the background and rationale on treating fetuses and children suffering from osteogenesis imperfecta (OI) with mesenchymal stem cells (MSCs). MSCs ability to migrate, engraft, and differentiate into bone cells and to act via paracrine effects on the recipient’s tissues makes these cells promising candidates as a clinical therapy for OI. Animal work and limited clinical studies in humans support the use of MSC in treating OI. Off-the-shelf MSC have a good safety profile and exhibit multilineage differentiation potential and a low immunogenic profile and thereby may enable this potential therapy to become widely available. MSC transplantation before and after birth to treat OI is an experimental therapy that is currently tested in the international multicentre phase I/II clinical trial BOOSTB4 that aims to assess the safety and efficacy of fetal MSC transplantation for the treatment of severe types of OI.Keywords
This publication has 27 references indexed in Scilit:
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical TrialsPLOS ONE, 2012
- Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue propertiesBlood, 2011
- In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfectaBlood, 2009
- Superior Osteogenic Capacity for Bone Tissue Engineering of Fetal Compared with Perinatal and Adult Mesenchymal Stem CellsStem Cells, 2009
- Comparative osteogenic transcription profiling of various fetal and adult mesenchymal stem cell sourcesDifferentiation, 2008
- Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta miceBlood, 2008
- Widespread Distribution and Muscle Differentiation of Human Fetal Mesenchymal Stem Cells After Intrauterine Transplantation in Dystrophic mdx MouseStem Cells, 2006
- Immunologic properties of human fetal mesenchymal stem cellsAmerican Journal of Obstetrics and Gynecology, 2004
- HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cellsExperimental Hematology, 2003
- Multilineage Potential of Adult Human Mesenchymal Stem CellsScience, 1999